[go: up one dir, main page]

MX356754B - Formas cristalinas de un modulador del receptor androgenico. - Google Patents

Formas cristalinas de un modulador del receptor androgenico.

Info

Publication number
MX356754B
MX356754B MX2014015005A MX2014015005A MX356754B MX 356754 B MX356754 B MX 356754B MX 2014015005 A MX2014015005 A MX 2014015005A MX 2014015005 A MX2014015005 A MX 2014015005A MX 356754 B MX356754 B MX 356754B
Authority
MX
Mexico
Prior art keywords
androgen receptor
receptor modulator
crystalline forms
modulator
trifluoromethylpyridin
Prior art date
Application number
MX2014015005A
Other languages
English (en)
Other versions
MX2014015005A (es
Inventor
Nicholas D Smith
Anna Dilhas
Ouathek Ouerfelli
Mark R Herbert
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356754(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MX2014015005A publication Critical patent/MX2014015005A/es
Publication of MX356754B publication Critical patent/MX356754B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se describe formas amorfas y cristalinas del modulador del receptor androgénico 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-dia zaspiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida; además, se describen composiciones farmacéuticas adecuadas para administrar a un mamífero que incluyen el modulador del receptor androgénico y métodos para usar el modulador del receptor androgénico, solo o en conjunto con otros compuestos, para tratar enfermedades o afecciones asociadas con la actividad del receptor androgénico.
MX2014015005A 2012-06-07 2013-06-04 Formas cristalinas de un modulador del receptor androgenico. MX356754B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (2)

Publication Number Publication Date
MX2014015005A MX2014015005A (es) 2015-09-04
MX356754B true MX356754B (es) 2018-06-11

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015005A MX356754B (es) 2012-06-07 2013-06-04 Formas cristalinas de un modulador del receptor androgenico.

Country Status (44)

Country Link
US (9) US9481663B2 (es)
EP (4) EP3533792B1 (es)
JP (3) JP6182209B2 (es)
KR (2) KR102062024B1 (es)
CN (3) CN113135892A (es)
AU (3) AU2013271751B2 (es)
BR (1) BR112014030678A2 (es)
CA (4) CA2875767C (es)
CL (1) CL2014003331A1 (es)
CO (1) CO7240407A2 (es)
CR (2) CR20190331A (es)
CY (4) CY1120393T1 (es)
DK (3) DK2858985T3 (es)
EA (3) EA028791B1 (es)
EC (1) ECSP14030098A (es)
ES (3) ES2875932T3 (es)
FR (1) FR21C1050I2 (es)
GT (1) GT201400283A (es)
HK (2) HK1210175A1 (es)
HR (3) HRP20180902T1 (es)
HU (4) HUE050357T2 (es)
IL (4) IL236055A0 (es)
IN (1) IN2014DN10084A (es)
LT (4) LT3533792T (es)
LU (1) LUC00236I2 (es)
ME (2) ME03815B (es)
MX (1) MX356754B (es)
MY (1) MY187500A (es)
NI (1) NI201400142A (es)
NO (1) NO2021046I1 (es)
NZ (2) NZ717683A (es)
PE (2) PE20150631A1 (es)
PH (2) PH12014502714A1 (es)
PL (3) PL3533792T3 (es)
PT (3) PT2858985T (es)
RS (3) RS60617B1 (es)
SG (3) SG10201610248SA (es)
SI (3) SI2858985T1 (es)
SM (3) SMT202100355T1 (es)
TR (1) TR201808939T4 (es)
TW (1) TWI532732B (es)
UA (2) UA115665C2 (es)
WO (1) WO2013184681A1 (es)
ZA (1) ZA201500076B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2385960B1 (en) 2009-01-12 2020-03-11 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
PE20150631A1 (es) 2012-06-07 2015-05-11 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador del receptor androgenico
RS62676B1 (sr) 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP2922888B1 (en) 2012-11-21 2021-08-18 The University of Massachusetts High strength polyisobutylene polyurethanes
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3186247B1 (en) * 2014-08-26 2021-03-03 Astar Biotech LLC Protein kinase inhibitors
PL3226841T3 (pl) 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
ES2839128T3 (es) 2014-12-05 2021-07-05 Aragon Pharmaceuticals Inc Composiciones anticancerosas
UA123538C2 (uk) * 2014-12-05 2021-04-21 Араґон Фармасьютікалз, Інк. Протиракові композиції
MX2017008050A (es) 2014-12-19 2018-01-18 Lutron Electronics Co Accesorio de iluminacion multicanal que tiene controladores de diodo emisor de luz.
BR112018074965A2 (pt) 2016-06-03 2019-03-12 Aragon Pharmaceuticals, Inc. composições anticancerígenas
WO2018112001A1 (en) 2016-12-13 2018-06-21 Watson Laboratories Inc. Solid state forms of apalutamide
EP3592786B1 (en) 2017-03-07 2023-05-10 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
US10835638B2 (en) 2017-08-17 2020-11-17 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
JP7201694B2 (ja) 2017-10-16 2023-01-10 アラゴン ファーマシューティカルズ，インコーポレイテッド 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019143629A1 (en) 2018-01-17 2019-07-25 Cardiac Pacemakers, Inc. End-capped polyisobutylene polyurethane
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) * 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
LT3100727T (lt) 2006-03-27 2018-12-10 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
CN101460467B (zh) * 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
KR101819199B1 (ko) * 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
PE20150631A1 (es) 2012-06-07 2015-05-11 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador del receptor androgenico
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof

Also Published As

Publication number Publication date
WO2013184681A1 (en) 2013-12-12
CY2021032I2 (el) 2022-03-24
EA201492272A1 (ru) 2015-05-29
KR20190132543A (ko) 2019-11-27
EP2858985A4 (en) 2016-05-25
AU2013271751A1 (en) 2014-12-18
PH12016501470B1 (en) 2021-12-10
PT2858985T (pt) 2018-07-10
PH12014502714B1 (en) 2015-02-02
EP3348553B1 (en) 2020-07-08
US20210163441A1 (en) 2021-06-03
GT201400283A (es) 2017-07-03
HRP20201387T1 (hr) 2020-11-27
JP6182209B2 (ja) 2017-08-16
CR20190331A (es) 2019-11-12
AU2017279807B2 (en) 2018-11-08
US9994545B2 (en) 2018-06-12
EP3922629A1 (en) 2021-12-15
LT2858985T (lt) 2018-09-25
HUE054595T2 (hu) 2021-09-28
ME03815B (me) 2021-04-20
SG11201408140QA (en) 2015-01-29
CA2875767A1 (en) 2013-12-12
EP2858985A1 (en) 2015-04-15
HK1226066A1 (zh) 2017-09-22
CA3055660A1 (en) 2013-12-12
JP2015518890A (ja) 2015-07-06
ME03081B (me) 2019-01-20
EP3348553A1 (en) 2018-07-18
EA201791592A1 (ru) 2018-01-31
AU2017200298A1 (en) 2017-02-02
NZ717683A (en) 2018-04-27
BR112014030678A2 (pt) 2017-06-27
KR20150021993A (ko) 2015-03-03
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11
US20190241539A1 (en) 2019-08-08
RS61988B1 (sr) 2021-07-30
IL267608A (en) 2019-08-29
FR21C1050I1 (fr) 2021-12-10
CR20140549A (es) 2015-04-06
CY1120393T1 (el) 2019-07-10
US9481663B2 (en) 2016-11-01
RS57370B1 (sr) 2018-08-31
NZ702203A (en) 2016-09-30
CY2021032I1 (es) 2022-03-24
SG10201610249TA (en) 2017-02-27
US10766875B2 (en) 2020-09-08
US20200354335A1 (en) 2020-11-12
EA033956B1 (ru) 2019-12-13
AU2017200298B2 (en) 2017-09-28
IL259738A (en) 2018-07-31
MX2014015005A (es) 2015-09-04
SI3348553T1 (sl) 2020-11-30
HUS2100047I1 (hu) 2021-11-29
SI2858985T1 (sl) 2018-12-31
CO7240407A2 (es) 2015-04-17
SMT202100355T1 (it) 2021-07-12
IL259738B (en) 2021-06-30
NO2021046I1 (no) 2021-11-02
SMT201800311T1 (it) 2018-07-17
ECSP14030098A (es) 2016-01-29
US20180258067A1 (en) 2018-09-13
US10308630B2 (en) 2019-06-04
CN105693692A (zh) 2016-06-22
UA115665C2 (uk) 2017-12-11
TW201402561A (zh) 2014-01-16
AU2017279807A1 (en) 2018-01-25
PL3348553T3 (pl) 2021-02-08
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
ES2809738T3 (es) 2021-03-05
MY187500A (en) 2021-09-24
EP2858985B1 (en) 2018-04-18
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
CA3008345C (en) 2019-10-22
PH12014502714A1 (en) 2015-02-02
US20190330182A1 (en) 2019-10-31
IL236055A0 (en) 2015-02-01
CY1124831T1 (el) 2022-03-24
EA028791B1 (ru) 2017-12-29
US20250092011A1 (en) 2025-03-20
KR102195916B1 (ko) 2020-12-30
CL2014003331A1 (es) 2016-03-04
SG10201610248SA (en) 2017-02-27
JP2018141009A (ja) 2018-09-13
HK1210175A1 (en) 2016-04-15
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
PT3533792T (pt) 2021-06-07
CY1123427T1 (el) 2021-12-31
PE20200725A1 (es) 2020-07-21
LT3533792T (lt) 2021-07-26
EP3533792B1 (en) 2021-05-05
FR21C1050I2 (fr) 2024-05-24
HUE038082T2 (hu) 2018-09-28
TWI532732B (zh) 2016-05-11
RS60617B1 (sr) 2020-09-30
ZA201500076B (en) 2016-10-26
PH12016501470A1 (en) 2017-07-10
US12018008B2 (en) 2024-06-25
PL2858985T3 (pl) 2018-09-28
CA3114726A1 (en) 2013-12-12
AU2013271751B2 (en) 2017-02-23
CA2875767C (en) 2018-08-14
US20170001977A1 (en) 2017-01-05
HRP20180902T1 (hr) 2018-08-24
US10556882B2 (en) 2020-02-11
US20150133481A1 (en) 2015-05-14
US20200115361A1 (en) 2020-04-16
JP6345821B2 (ja) 2018-06-20
TR201808939T4 (tr) 2018-07-23
LUC00236I2 (es) 2025-02-03
JP2017178923A (ja) 2017-10-05
LT3348553T (lt) 2020-09-25
HRP20210909T1 (hr) 2021-09-03
PT3348553T (pt) 2020-09-28
PE20150631A1 (es) 2015-05-11
EA201992010A1 (ru) 2020-01-24
CA3008345A1 (en) 2013-12-12
EP3533792A1 (en) 2019-09-04
US10526310B2 (en) 2020-01-07
DK3348553T3 (da) 2020-07-27
PL3533792T3 (pl) 2021-11-29
IN2014DN10084A (es) 2015-08-21
IL275413A (en) 2020-07-30
DK3533792T3 (da) 2021-06-28
CN104619692A (zh) 2015-05-13
CN113135892A (zh) 2021-07-20
SI3533792T1 (sl) 2021-11-30
LTPA2021525I1 (es) 2021-11-25
UA123142C2 (uk) 2021-02-24

Similar Documents

Publication Publication Date Title
PH12016501470A1 (en) Crystalline forms of an androgen receptor modulator
NZ702663A (en) Nuclear transport modulators and uses thereof
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
PH12014500355A1 (en) Lysophosphatidic acid receptor antagonists
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
HK1182015A1 (zh) 活性藥物化合物用於治療中樞神經系統病症的用途
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
MX2015012043A (es) Agonistas muscarinicos.
MX2015002514A (es) Antagonistas de los receptores de quimiocina.
WO2015079415A9 (en) Amorphous cobicistat solid dispersion
MX2014011922A (es) Composicion para el tratamiento de desordenes inflamantorios e inmunes.

Legal Events

Date Code Title Description
FG Grant or registration